AVITA Medical, Inc. (FRA:51KA)

Market Cap	89.36M
Revenue (ttm)	61.71M
Net Income (ttm)	-41.38M
Shares Out	n/a
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	315
Open	2.820
Previous Close	2.720
Day's Range	2.820 - 2.820
52-Week Range	2.680 - 9.900
Beta	n/a
RSI	26.72
Earnings Date	Feb 12, 2026

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Cary Vance
• Employees: 260
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51KA

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Financial numbers in USD